Stabile pharmaceutical compound comprises mixture of: anti-α4β7 antibodies, citrate, surfactant and, at least, one free amino acid, with certain molar coorelation, wherein variable parts of amino acid sequences of heavy and light chains of anti-α4β7 antibodies are specified. Said pharmaceutical compound is used at inflammatory bowel disease (IBD) treatment.